Invention Grant
- Patent Title: Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
-
Application No.: US14668683Application Date: 2015-03-25
-
Publication No.: US09358297B2Publication Date: 2016-06-07
- Inventor: Susan K. Heimbecher , David Monteith , James D. Pipkin
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Richard S. Parr; Catherine D. Fitch
- Main IPC: A61K9/00
- IPC: A61K9/00 ; A61K47/40 ; A61K31/496 ; A61K31/724
Abstract:
The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified β-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.
Public/Granted literature
- US20150265715A1 POSACONAZOLE INTRAVENOUS SOLUTION FORMULATIONS STABILIZED BY SUBSTITUTED BETA-CYCLODEXTRIN Public/Granted day:2015-09-24
Information query
